The world is getting older, wealthier and more health conscious. From menopause and diabetes to intimate health and everyday wound care, consumers are increasingly taking charge of their own wellbeing – helped by better science, improved distribution and a desire to treat common conditions earlier, faster and more conveniently.
Step forward Venture Life Group plc , the consumer healthcare products group, who today announced the transformational acquisition of US brands FemiClear and CUROXEN (re asset purchase) from OrganiCare, LLC for up to $28m (or 1.9x Ev/sales and 6.1x Ev/contribution). On top, #VLG will also invest approx $1.6m in working capital (or c. 13% turnover).
For me, this deal looks bang on strategy. FemiClear addresses common gynaecological conditions such as bacterial vaginosis, genital herpes, thrush and UTIs, while CUROXEN targets infection prevention for wounds and mouth sores. Better still, the transaction immediately provides #VLG scale in the huge US women’s intimate health market, alongside relationships with major retailers including Walmart, Walgreens, CVS and Target.
The numbers are encouraging too. The brands generated $12.1m of sales in the 12 months to March 2026, up 29.1%, with gross profit of $7.5m and contribution of $3.6m. Over the past two years, revenues have compounded at 22.5%, with FemiClear representing around 98% of the financial performance. Encouragingly, momentum appears to be accelerating too, with Q4 turnover up 39.7% YoY, helped by Target launches and range extensions.
Strategically, the acquisition should do three important things. First, it broadens VLG’s women’s health franchise beyond Balance Activ into adjacent, high-growth treatment categories. Second, it offers a scalable US commercial platform for launching other Venture Life brands. Third, it should be margin enhancing, with synergies from distribution, product development and operational efficiencies expected to build from 2027.
CEO Jerry Randall said the brands are “highly complementary”, “margin enhancing” and provide “an essential, scalable platform for growth in the US market and women’s intimate health category.”
Elsewhere trading is being driven by four main factors. Revenue growth is strong, and importantly volume-led rather than price-led. Higher advertising and promotional spend is boosting UK Power Brand sales, albeit temporarily weighing on EBITDA margins. International performance has been lumpy due to order timing and distributor destocking, though this has since normalised.
Indeed, acquisitions such as Health & Her and now FemiClear/CUROXEN are reshaping VLG into a capital-light, branded healthcare platform with greater operating leverage.
Lastly in terms of the numbers (ie prior to today’s acquisition), Cavendish was forecasting May FY’26 revenue of £50.4m, EBITDA £8.0m, and EPS of 4.1p, alongside a 100p target price.
Disclosure: Venture Life Group plc is a Vox Markets client.